Inventor · South San Francisco, CA, US

Deepak Sampath

17Patents
4h-index
30Co-inventors
56Inventor score

Filing activity: Sep 10, 2008 → Jun 7, 2022

Most-cited inventions

PatentTitleAreaCited byStatus
US8604014B2 Combinations of phosphoinositide 3-kinase inhibitor compounds chemotherapeutic agents, and methods of use Emerging Cross-Sectional Technologies 25 Active
US8247397B2 Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use Emerging Cross-Sectional Technologies 24 Active
US9107926B2 Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer Chemistry; Metallurgy 23 Active
US9539251B2 Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor Chemistry; Metallurgy 11 Active
US11110087B2 Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor Chemistry; Metallurgy 4 Active
US9150549B2 Combinations of AKT inhibitor compounds and erlotinib, and methods of use Human Necessities 4 Active
US9682082B2 Combinations of AKT and MEK inhibitor compounds, and methods of use Chemistry; Metallurgy 4 Active
US11413282B2 Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor Chemistry; Metallurgy 3 Active
US9855270B2 Methods and compositions for modulating estrogen receptor mutants Chemistry; Metallurgy 3 Active
US10993942B2 Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor Chemistry; Metallurgy 3 Active
US9610289B2 Combinations of AKT inhibitor compounds and erlotinib, and methods of use Human Necessities 2 Active
US9346789B2 Combinations of AKT inhibitor compounds and abiraterone, and methods of use Human Necessities 2 Active
US10092567B2 Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use Human Necessities 2 Active
US11590128B2 Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor Chemistry; Metallurgy 2 Active
US10898570B2 Combination therapy with an anti-HER2 antibody-drug conjugate and a Bcl-2 inhibitor Physics 2 Active
US10959993B2 Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer Human Necessities 1 Active
US9717730B2 Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use Human Necessities 1 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.